Jungsu Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5713141/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tubular human brain organoids to model microglia-mediated neuroinflammation. Lab on A Chip, 2021, 21, 2751-2762.	3.1	41
2	MicroRNAs on the move: microRNAs in astrocyte-derived ApoE particles regulate neuronal function. Neuron, 2021, 109, 907-909.	3.8	2
3	Deletion of <i>Abi3</i> gene locus exacerbates neuropathological features of Alzheimer's disease in a mouse model of Al² amyloidosis. Science Advances, 2021, 7, eabe3954.	4.7	26
4	Acoustofluidic assembly of 3D neurospheroids to model Alzheimer's disease. Analyst, The, 2020, 145, 6243-6253.	1.7	44
5	Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy. Acta Neuropathologica Communications, 2020, 8, 72.	2.4	42
6	MicroRNA 7 Impairs Insulin Signaling and Regulates A <i>β</i> Levels through Posttranscriptional Regulation of the Insulin Receptor Substrate 2, Insulin Receptor, Insulin-Degrading Enzyme, and Liver X Receptor Pathway. Molecular and Cellular Biology, 2019, 39, .	1.1	51
7	Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Current Opinion in Lipidology, 2017, 28, 60-67.	1.2	123
8	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	3.9	90
9	Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery. Scientific Reports, 2017, 7, 12720.	1.6	18
10	APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. Molecular Neurodegeneration, 2017, 12, 12.	4.4	25
11	[P4–125]: THE MOLECULAR CHAPERONE BRICHOS INHIBITS Aβ AGGREGATION AND OTHER NEUROPATHOLOGICAL PHENOTYPES IN A MOUSE MODEL OF Aβ AMYLOIDOSIS. Alzheimer's and Dementia, 2017, 13, P1304.	0.4	0
12	miRâ€186 is decreased in aged brain and suppresses <scp>BACE</scp> 1 expression. Journal of Neurochemistry, 2016, 137, 436-445.	2.1	78
13	P4â€059: Agingâ€Associated Micrornaâ€186â€5P Regulates Abeta Level Through Bace1. Alzheimer's and Demen 2016, 12, P1037.	itia. 0.4	0
14	A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway. Journal of Alzheimer's Disease, 2016, 51, 591-604.	1.2	21
15	miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Molecular Neurodegeneration, 2016, 11, 55.	4.4	106
16	O5-03-01: Apolipoprotein E Genotype Differentially Modulates Effects of ANTI-AB Immunotherapy. , 2016, 12, P381-P382.		1
17	MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 2139-2147.	1.2	18
18	Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival. Scientific Reports, 2016, 6, 23326.	1.6	31

Jungsu Kim

#	Article	IF	CITATIONS
19	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
20	Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-β Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 109-122.	1.2	25
21	Special issue on neurodegenerative diseases and their therapeutic approaches. Experimental and Molecular Medicine, 2015, 47, e146-e146.	3.2	5
22	Mitochondrial ATP synthase activity is impaired by suppressed <i>O</i> -GlcNAcylation in Alzheimer's disease. Human Molecular Genetics, 2015, 24, 6492-6504.	1.4	74
23	The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis. Science Translational Medicine, 2015, 7, 314ra184.	5.8	30
24	microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain. Journal of Neuroscience, 2015, 35, 14717-14726.	1.7	104
25	Apolipoprotein E in Synaptic Plasticity and Alzheimer's Disease: Potential Cellular and Molecular Mechanisms. Molecules and Cells, 2014, 37, 767-776.	1.0	113
26	Analysis of Extracellular RNA by Digital PCR. Frontiers in Oncology, 2014, 4, 129.	1.3	38
27	Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity. Inorganic Chemistry, 2014, 53, 11367-11376.	1.9	43
28	Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis. Journal of Neuroscience, 2014, 34, 7281-7292.	1.7	102
29	Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	42
30	Blocking the apoE/Aß interaction ameliorates Aß-related pathology in APOE ¿2 and ¿4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	36
31	Normal cognition in transgenic BRI2-AÎ ² mice. Molecular Neurodegeneration, 2013, 8, 15.	4.4	74
32	The effect of Cu2+ and Zn2+ on the Al̂²42 peptide aggregation and cellular toxicity. Metallomics, 2013, 5, 1529.	1.0	114
33	Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Experimental Neurology, 2013, 239, 192-201.	2.0	117
34	Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration. American Journal of Pathology, 2013, 182, 1750-1768.	1.9	70
35	Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB Journal, 2013, 27, 187-198.	0.2	254
36	Control of Cholesterol Metabolism and Plasma High-Density Lipoprotein Levels by microRNA-144. Circulation Research, 2013, 112, 1592-1601.	2.0	187

Јимсѕи Кім

#	Article	IF	CITATIONS
37	Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 38.	3.0	48
38	Role of Autophagy in Alzheimer's Disease. Current Enzyme Inhibition, 2013, 9, 55-66.	0.3	1
39	Editorial (Hot Topic Therapeutic Targets in Neurodegenerative Diseases). Current Enzyme Inhibition, 2013, 9, 1-2.	0.3	0
40	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. Journal of Experimental Medicine, 2012, 209, 2149-2156.	4.2	120
41	Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ ₄₂ Peptide. Journal of the American Chemical Society, 2012, 134, 6625-6636.	6.6	187
42	APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2012, 287, 41774-41786.	1.6	213
43	Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling. Molecular Neurodegeneration, 2012, 7, 14.	4.4	23
44	Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of AÎ ² Uptake and Degradation by Astrocytes. Journal of Biological Chemistry, 2012, 287, 13959-13971.	1.6	152
45	miR-106b impairs cholesterol efflux and increases AÎ ² levels by repressing ABCA1 expression. Experimental Neurology, 2012, 235, 476-483.	2.0	161
46	In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS. PLoS ONE, 2012, 7, e38013.	1.1	43
47	Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease. International Journal of Clinical and Experimental Pathology, 2012, 5, 482-95.	0.5	13
48	Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis. Journal of Neuroscience, 2011, 31, 18007-18012.	1.7	166
49	Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance. Science Translational Medicine, 2011, 3, 89ra57.	5.8	924
50	Serotonin signaling is associated with lower amyloid-Î ² levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14968-14973.	3.3	281
51	Tutorial on Drug Development for Central Nervous System. Interdisciplinary Bio Central, 2010, 2, 9.1-9.5.	0.1	0
52	Differential Effects of ApoE Isoforms on Dendritic Spines <i>In Vivo</i> : Linking an Alzheimer's Disease Risk Factor with Synaptic Alterations. Journal of Neuroscience, 2010, 30, 4526-4527.	1.7	4
53	Prion-Like Behavior of Amyloid-β. Science, 2010, 330, 918-919.	6.0	26
54	The roles of GxxxG motif and gamma-secretase components in APP processing. Interdisciplinary Bio Central, 2009, 1, 1-7.	0.1	2

Јинсѕи Кім

#	Article	IF	CITATIONS
55	The Role of Apolipoprotein E in Alzheimer's Disease. Neuron, 2009, 63, 287-303.	3.8	1,251
56	Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Al ² Clearance. Neuron, 2009, 64, 632-644.	3.8	212
57	BRI2 (ITM2b) Inhibits AÂ Deposition In Vivo. Journal of Neuroscience, 2008, 28, 6030-6036.	1.7	110
58	Amyloid precursor protein-induced axonopathies are independent of amyloid-β peptides. Human Molecular Genetics, 2008, 17, 3474-3486.	1.4	68
59	Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. Journal of Clinical Investigation, 2008, 118, 671-82.	3.9	301
60	AÂ40 Inhibits Amyloid Deposition In Vivo. Journal of Neuroscience, 2007, 27, 627-633.	1.7	327
61	Insights into the mechanisms of action of antiâ€Aβ antibodies in Alzheimer's disease mouse models. FASEB Journal, 2006, 20, 2576-2578.	0.2	110
62	Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron, 2005, 47, 191-199.	3.8	524
63	CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human Molecular Genetics, 2004, 13, 703-714.	1.4	613